Synergistic interaction between cisplatin and gemcitabine in vitro

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 521-530

  Bergman, Andries M ^a   Ruiz Van Haperen, Veronique W T ^a   Veerman, Gijsbert ^a   Kuiper, Catharina M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CISPLATIN; DEOXYCYTIDINE; DNA; DNA DAMAGE; DRUG SYNERGISM; HUMANS; TUMOR CELLS, CULTURED;

EID: 0029875635     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C , and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50. 4417-4422, 1990.
2. Braakhuis, B. J. M., van Dongen, G. A. M. S., Vermorken, J. B., and Snow, G. B. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against head and neck cancer. Cancer Res., 51: 211-214, 1991.
3. Boven, E., Schipper, H., Erkelens, C. A. M., Hatty, S. A., and Pinedo, H. M. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br. J. Cancer. 68: 52-56, 1993.
4. Kaye, S. B. Gemcitabine: current status of Phase I and II trials. J. Clin. Oncol., 12: 1527-1531, 1994.
5. Abratt, R. P., Rezwoda, W., Falkson, G., Goedhals, L., and Hacking, D. Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study. J. Clin. Oncol., 12: 1535-1540, 1994.
6. Lund, B., Hansen, O. P., Theilade, K., Hansen, M., and Neijt, J. P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst., 86: 1530-1533, 1994.
7. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
8. Ruiz van Haperen, V. W. T., Veerman, G., Vermerken, J. B., and Peters, G. J. 2′,2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem. Pharmacol., 46: 762-766, 1993.
9. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
10. Muggia, F. Introduction: cisplatin update. Semin. Oncol., 18 (Suppl. 3): 1-4, 1991.
11. Roberts, J. J., Thomson, A. J. The mechanism of action of antitumour platinum compounds. Prog. Nucleic Acid Res. Mol. Biol., 22: 71-133, 1979.
12. Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., and Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry, 24: 707-713, 1985.
13. Fichtinger-Schepman, A. M. J. Variability in DNA-adduct levels after in vivo treatment with the antitumor drug cisplatin. J. Inorg. Biochem , 39: 154-58, 1989.
14. Terheggen, P. M. A. B., Emondt, J. Y., Floot, B. G. J., Dijkman, R., Schrier, P. I., Den Engelse, L., and Begg A. C. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Rev., 50. 3556-3561, 1990.
15. Terheggen, P. M. A. B., Begg, A. C., Emondt, J. Y., Dubbelman, R., Floot, B. G. J., and den Engelse L. Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. Br. J. Cancer, 63: 195-200, 1991
16. Parker, R. J., Gill, I., Tarone, R., Vionnet, J., Grunberg, S., Muggia, F., and Reed E. Platinum DNA-damage in leucocyte DNA of patients receiving cisplatin and carboplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (Lond.), 12: 1253-1258, 1991.
17. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirier, M. C. Platinum DNA-damage in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. USA, 84: 5024-5028, 1987.
18. Brabec, V., Kleinwachter, V., Butour, J. L., and Johnson, N. P. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys. Chem., 35: 129-141, 1990.
19. Abbruzzese, J. L., and Frost, P. Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and CDDP. Cancer Chemother. Pharmacol., 30: 31-36, 1982.
20. Fram, R. J., Robichaud, N., Bishov, S. D., and Wilson, J. M. Interactions of cis-diamminedichloroplatinum(II) with 1-β-D-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res., 47: 3360-3365, 1987.
21. Smith, S. L., and Douglas, K. T. Stereoselective, strong inhibition of ribonucleotide reduciase from E Coli by cisplatin. Biochem. Biophys. Res. Commun., 162: 715-723, 1989.
22. Lu, Y., Han, J., and Scanlon, K. J. Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J. Biol. Chem., 263: 4891-4894, 1988.
23. Ruiz van Haperen, V. W. T., Veerman, G., Eriksson, S., Boven, E., Stegmann, A. P. A., Hermsen, M., Vermorken, J B , Pinedo, H. M., and Peters, G. J. Development and characterization of a 2′,2′-difiuorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Res., 54: 4138-4143, 1994.
24. Carey, T. E. Establishment of epidermoid carcinoma cell lines. In: R. E. Wines (ed.) Head and Neck Cancer, pp. 287-314. New York: John Wiley & Sons, 1985.
25. Peters, G. J., Kraal, I., and Pinedo, H. M. In vitro and in vivo studies on the combination of brequinar sodium (DUP 785, NSC 368390) with 5-fluorouracil, effects of uridine. Br. J. Cancer, 65: 229-233, 1992.
26. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
27. Keepers, Y. P., Pizao, P. E., Peters, G. J., Van Ark-Otte, J., Winograd, B., and Pinedo, H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer, 27: 897-900, 1991.
28. Peters, G. J., Wets, M., Keepers, Y. P. A. M., Oskam, R., Van Ark-One, J., Noordhuis, P., Smid, K., and Pinedo, H. M. Transformation of mouse fibroblasts with the oncogenes H-ray or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer, 54: 450-455, 1993
29. Chou, T. C., Talalay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs on enzyme inhibitors. In: G. Weber (ed.) Advances in Enzyme Regulation, pp. 27-55. New York: Pergamon Press, 1983.
30. Greco, W. R., Bravo, G., and Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 47: 331-385, 1995.
31. Steel, G. G., and Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Im. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
32. Ruiz van Haperen, V. W. T., Veerman, G., Boven, E., Noordhuis, P., Vermorken, J. B., and Peters G. J. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem. Pharmacol., 48: 1327-1339, 1994.
33. Birnboim, H. C., and Jevcak, J. J. Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res., 41: 1889-1892, 1981.
34. Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Zijlstra, J. G., and De Vries, E. G. E. Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res., 47: 4613-4617, 1987.
35. Ellerhorst, J. A., Frost, P , Abbruzzese, J. L., Newman, R. A., and Chernajovsky, Y. 2′-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br. J. Cancer, 67: 209-215, 1993.
36. Greco, W R., Hyoung, S. P., and Rustum, Y. M. Application to a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res., 50: 5318-5327, 1990.
37. Yang, L Y., Li, L., Liu, X M., Keating, M. J., and Plunkett, W. Gemcitabine suppresses the repair of cisplatin adducts in plasmid DNA by extracts of cisplatin-resistant human colon carcinoma cells. Proc. Am. Assoc. Cancer Res., 36: 357, 1995.
38. Bergerat, J. P., Drewinko, B., Corry, P., Barlogie, B., and Ho, D. H. Synergistic lethal effect of cis-diamminedichloroplatinum and I-β-D-arabino furanosyl cytosine. Cancer Res., 41: 25-30, 1981.
39. Waldren, C. A., and Rasko, I. Caffeine enhancement of X-ray killing in cultured human and rodent cells. Radiat Res., 73: 95-110, 1987.
40. Byfield, J. E. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. Br. J. Cancer., 43: 667-683, 1981.
41. Ross, D. D., and Cuddy, D. P. Molecular effect of 2′,2′-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem. Pharmacol , 48: 1619-1630, 1994.
42. Jackson, R. C. Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. Cancer Res., 53: 3998-4003, 1993.